Resources Repository
-
ReportPublication 2017Economic Value of Informal Mental Health Caring
Caregivers, family and friends play a significant role in supporting people with mental illness, and …
Caregivers, family and friends play a significant role in supporting people with mental illness, and it has long been recognized that informal carers constitute a significant ‘hidden’ workforce in Australia. Faced as Australia is with an ageing population and burgeoning chronic disease, data on the contribution that carers make and the consequent savings to governments and other ‘payers’ need to be articulated. This report attempts to put a ‘value’ on informal caring for those with mental illness.…
Oceania | Mental Health | Preferences/Values | Costing Methods | Health Outcomes | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
North America | Mental Health | Preferences/Values | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
State-Transition | North America | Mental Health | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Oceania | Mental Health | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Health/Medicine | Asia & Pacific -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
North America | Mental Health | Preferences/Values | Costing Methods | Benefit-Cost Analysis | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2012Modeling the Risks and Benefits of Depression Treatment for Children and Young Adults
This article, published in Value in Health, presents a discrete event simulation model to quantify …
This article, published in Value in Health, presents a discrete event simulation model to quantify the trade-offs with respect to clinical benefits and the risk of fatal and non-fatal suicidal behavior of alternative treatment strategies for a U.S. pediatric population with major depressive disorder. The authors evaluate treatment strategies including: selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and a combination of both. The results show that the use of SSRIs is associated with…
North America | Mental Health | Health Outcomes | Microsimulation | Technology Assessment | Health/Medicine